INmune Bio Inc
INMB2.795USD
+0.235+9.17%
Market hours （ET）Quotes delayed by 15 min
64.08MMarket Cap
LossP/E TTM
More Details of INmune Bio Inc Company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Company Info
Ticker SymbolINMB
Company nameINmune Bio Inc
IPO dateFeb 04, 2019
CEODr. Raymond J. Tesi, M.D.
Number of employees22
Security typeOrdinary Share
Fiscal year-endFeb 04
Address225 Ne Mizner Blvd, Suite 640
CityBOCA RATON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33432
Phone18589643720
Websitehttps://www.inmunebio.com/
Ticker SymbolINMB
IPO dateFeb 04, 2019
CEODr. Raymond J. Tesi, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
71.60K
+7.51%
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Dr. Raymond J. Tesi, M.D.
Dr. Raymond J. Tesi, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David J. Moss
Mr. David J. Moss
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Mr. J. Kelly Ganjei
Mr. J. Kelly Ganjei
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
71.60K
+7.51%
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Dr. Raymond J. Tesi, M.D.
Dr. Raymond J. Tesi, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David J. Moss
Mr. David J. Moss
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 4
Updated: Fri, Jul 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Xencor Inc
7.09%
Tesi (Raymond Joseph)
5.85%
Lowdell (Mark William)
5.68%
Heights Capital Management, Inc.
5.64%
Moss (David J.)
4.84%
Other
70.90%
Shareholders
Shareholders
Proportion
Xencor Inc
7.09%
Tesi (Raymond Joseph)
5.85%
Lowdell (Mark William)
5.68%
Heights Capital Management, Inc.
5.64%
Moss (David J.)
4.84%
Other
70.90%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.52%
Investment Advisor
16.98%
Corporation
7.09%
Hedge Fund
5.38%
Investment Advisor/Hedge Fund
4.28%
Research Firm
0.82%
Bank and Trust
0.20%
Venture Capital
0.14%
Private Equity
0.14%
Other
47.45%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
165
14.02M
52.73%
+503.40K
2025Q1
165
12.97M
59.27%
-484.99K
2024Q4
147
12.96M
58.46%
+804.75K
2024Q3
134
11.81M
53.27%
+318.25K
2024Q2
123
11.15M
54.62%
+1.47M
2024Q1
101
9.25M
51.52%
+199.50K
2023Q4
97
8.79M
48.95%
-237.73K
2023Q3
92
8.63M
48.03%
-362.72K
2023Q2
91
8.66M
48.24%
-1.19M
2023Q1
99
8.27M
46.11%
-1.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Xencor Inc
1.89M
7.09%
+62.00
+0.00%
Apr 14, 2025
Tesi (Raymond Joseph)
1.55M
5.85%
--
--
Apr 14, 2025
Lowdell (Mark William)
1.51M
5.68%
--
--
Apr 14, 2025
Heights Capital Management, Inc.
1.50M
5.64%
+1.50M
--
Jun 27, 2025
Moss (David J.)
1.29M
4.84%
--
--
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
875.69K
3.29%
+10.58K
+1.22%
Mar 31, 2025
Praetorian Capital Management, L.L.C.
865.00K
3.25%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
826.61K
3.11%
+88.41K
+11.98%
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
378.99K
1.43%
-94.56K
-19.97%
Mar 31, 2025
Geode Capital Management, L.L.C.
364.86K
1.37%
+1.26K
+0.35%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
